Radiotherapy and PD-L1 inhibition in metastatic NSCLC

Affiliations

¹ University Hospitals Leuven, Department of Radiation Oncology, B-3000 Leuven, Belgium; Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, 6229 Maastricht, The Netherlands. Electronic address: dirk.deruysscher@maastro.nl.

Comment

Dirk De Ruysscher. Lancet Oncol. 2017 Jul.

. 2017 Jul;18(7):840-842.

doi: 10.1016/S1470-2045(17)30354-6. Epub 2017 May 24.

¹ University Hospitals Leuven, Department of Radiation Oncology, B-3000 Leuven, Belgium; Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, 6229 Maastricht, The Netherlands. Electronic address: dirk.deruysscher@maastro.nl.

No abstract available

Comment on

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Shaverdian N, et al. Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24. Lancet Oncol. 2017. PMID: 28551359 Free PMC article. Clinical Trial.